This is a preview of subscription content, log in via an institution to check access.
Literatur
Antonia SJ et al. N Engl J Med. 2017;377(20):1919-29
Antonia SJ et al. N Engl J Med. 2018;379(24):2342-50
Bradley JD et al. Lancet Oncol. 2015;16(2):187-99
Pless M et al. Lancet. 2015;386(9998):1049-56
Eberhardt WE et al. J Clin Oncol. 2015;33(35):4194-201
Aupérin A et al. J Clin Oncol. 2010;28(13):2181-90
Arriagada R et al. N Engl J Med. 2004;350(4):351-60
Gray JE et al. J Clin Oncol. 2019;37(15_suppl):8526
Reck M et al. N Engl J Med. 2016;375(19):1823-33
Socinski MA et al. N Engl J Med. 2018;378(24):2288-2301
Popp I et al. Radiother Oncol. 2016;120(2):185-94
Peters S et al. Ann Oncol. 2019;30(2):161-5
De Ruysscher D et al. Radiother Oncol. 2017;124(1):1-10
Postmus PE et al. Ann Oncol. 2017;28(suppl_4):iv1-iv21
Twyman-Saint Victor C et al. Nature. 2015;520(7547):373-7
Vanpouille-Box C et al. Nat Commun. 2017;8:15618
Marciscano AE et al. Clin Cancer Res. 2018;24(20):5058-71
Dovedi SJ et al. Cancer Res. 2014;74(19):5458-68
Peters S et al. Lung Cancer. 2019;133:83-87
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guckenberger, M. Durvalumab nach Radiochemotherapie. InFo Hämatol Onkol 23, 32–33 (2020). https://doi.org/10.1007/s15004-020-8064-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15004-020-8064-x